Wednesday, August 5, 2026 is a landmark moment for Moderna — and potentially for vaccine history. The FDA’s PDUFA target action date for mFlusiva (mRNA-1010), Moderna’s seasonal influenza vaccine candidate, falls today, meaning the agency is expected to issue a final approval decision by market close. If approved, mFlusiva will become the first mRNA-based seasonal flu vaccine ever licensed in the United States, extending Moderna’s platform well beyond COVID-19 into a market that encompasses roughly 150 to 170 million flu shots administered each year in the U.S. alone.
The regulatory pathway here is unusually de-risked for a biotech catalyst. On June 18, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor of mFlusiva’s benefit-risk profile for adults aged 50 and older — a unanimous outcome that analysts described as exceeding expectations. Moderna’s Q2 2026 financial results, reported separately, showed the company narrowing losses from $825 million in Q2 2025 to $782 million in Q2 2026, while revenue of $145 million beat estimates of $103 million. Management also lowered 2026 operating expense guidance by $200 million, signaling improved cost discipline. The company is targeting up to 10% revenue growth from 2025 levels and expects roughly a 50/50 U.S.-international revenue split this year. MRNA shares have already more than doubled from their 2026 lows, hitting a 52-week intraday high of $81.40 in early July following the advisory committee vote.
For investors, an FDA approval today removes the single biggest near-term binary risk for Moderna. A green light means mFlusiva can move into distribution in time for the 2026-2027 flu season starting this fall — generating first commercial revenue from a product that addresses a market Moderna’s COVID franchise never touched. The U.S. flu vaccine market generates roughly $4 to $5 billion in annual revenue, and an mRNA-based product commanding a premium price could significantly alter Moderna’s revenue trajectory heading into 2027. The stock has historically moved 10 to 15% on major FDA outcomes, and with the unanimous panel backing already in place, the risk-reward leans toward approval. A rejection or a complete response letter — while unlikely given the 9-0 panel vote — would pressure shares meaningfully. Investors holding MRNA should watch for a press release from the FDA or Moderna by market close today.
